{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:31:20Z","timestamp":1770647480678,"version":"3.49.0"},"reference-count":81,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015169","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T15:57:25Z","timestamp":1730303845000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["First-line therapy for high-risk people with chronic lymphocytic leukemia: a network meta-analysis"],"prefix":"10.1002","volume":"2024","author":[{"given":"Kenichi","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Informatics, Graduate School of Medicine; Institute of Science Tokyo; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Ohmoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Cancer Institute Hospital of Japanese Foundation for Cancer Research; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Yoneoka","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Bioinformatics, Graduate School of Public Health; St. Luke\u2019s International University; Tokyo Japan"},{"name":"Center for Surveillance, Immunization, and Epidemiologic Research; National Institute of Infectious Diseases; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Obaidur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Center for Surveillance, Immunization, and Epidemiologic Research; National Institute of Infectious Diseases; Tokyo Japan"},{"name":"Department of Global Health Nursing, Graduate School of Nursing Science; St. Luke's International University; Tokyo Japan"},{"name":"Center for Evidence-Based Medicine and Clinical Research; Dhaka Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Global Health Nursing, Graduate School of Nursing Science; St. Luke's International University; Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD015169-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015169-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD015169-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD015169-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015169-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"Journal of Computational and Graphical Statistics"},{"issue":"9","key":"10.1002\/14651858.CD015169-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Bulian","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"10.1002\/14651858.CD015169-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD015169-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/bloodadvances.2017015396","article-title":"Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)","volume":"2","author":"Byrd","year":"2018","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD015169-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015169-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD015169-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1088\u201394","DOI":"10.3324\/haematol.2013.101378","article-title":"The clinical significance of patients\u2019 sex in chronic lymphocytic leukemia","volume":"99","author":"Catovsky","year":"2014","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD015169-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015169-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD015169-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Chaimani A Caldwell DM Li T Higgins JP Salanti G Chapter 11: Undertaking network meta-analyses (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch11"},{"issue":"27","key":"10.1002\/14651858.CD015169-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015169-BIB0016|cit16","unstructured":"CINeMA: Confidence in Network Meta-Analysis Papakonstantinou T Nikolakopoulou A Higgins JPT Egger M Salanti G Institute of Social and Preventive Medicine, University of Bern 2017"},{"key":"10.1002\/14651858.CD015169-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015169-BIB0018|cit18","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3115-3","volume-title":"Modelling Survival Data in Medical Research","author":"Collett","year":"1994"},{"key":"10.1002\/14651858.CD015169-BIB0019|cit19","unstructured":"Covidence Veritas Health Innovation 2022"},{"key":"10.1002\/14651858.CD015169-BIB0020|cit20","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015169-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015169-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making. 2: A generalized linear modelling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Medical Decision Making"},{"key":"10.1002\/14651858.CD015169-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making. 4: Inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Medical Decision Making"},{"key":"10.1002\/14651858.CD015169-BIB0024|cit24","doi-asserted-by":"crossref","DOI":"10.1002\/9781118951651","volume-title":"Network Meta-Analysis for Decision-Making","author":"Dias","year":"2018"},{"issue":"26","key":"10.1002\/14651858.CD015169-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015169-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD015169-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncology"},{"issue":"21","key":"10.1002\/14651858.CD015169-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1182\/blood-2014-01-547737","article-title":"Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL","volume":"123","author":"Geisler","year":"2014","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015169-BIB0029|cit29","first-page":"4159\u201361","article-title":"Initiating first-line (1L) ibrutinib (ibr) in patients (pts) with chronic lymphocytic leukemia (CLL) improves overall survival (OS) outcomes to rates approximating an age-matched population of \u2265 65 years","volume":"140","author":"Ghia","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD015169-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Binutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD015169-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.3324\/haematol.2017.169334","article-title":"The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies","volume":"102","author":"Golay","year":"2017","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD015169-BIB0032|cit32","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2023"},{"key":"10.1002\/14651858.CD015169-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Medical Research Methodology"},{"issue":"12","key":"10.1002\/14651858.CD015169-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"9747","key":"10.1002\/14651858.CD015169-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015169-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"306\u201313","DOI":"10.1002\/jrsm.1187","article-title":"'Arm-based\u2019 parameterization for network meta-analysis","volume":"7","author":"Hawkins","year":"2015","journal-title":"Research Synthesis Methods"},{"issue":"23","key":"10.1002\/14651858.CD015169-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD015169-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015169-BIB0039|cit39","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"13","key":"10.1002\/14651858.CD015169-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3603\u201312","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD015169-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015169-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12000","article-title":"Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial","volume":"159","author":"Knauf","year":"2012","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD015169-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.2005.03.7184","article-title":"Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia","volume":"24","author":"Kr\u00f6ber","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015169-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015169-BIB0045|cit45","unstructured":"Molica S Life expectancy improves when CLL is treated with target therapies International Workshop on Chronic Lymphocytic Leukemia; 2023 Oct 6-9; Boston (MA) Available at cllsociety.org\/2023\/11\/life expectancy-improves-when-cll-is-treated-with-target-therapies\/"},{"issue":"9","key":"10.1002\/14651858.CD015169-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"22","key":"10.1002\/14651858.CD015169-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"4393\u2013402","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD015169-BIB0048|cit48","unstructured":"NCCN Clinical Practice Guidelines in Oncology, Chronic Lymphocytic Leukemia\/ Small Lymphocytic Lymphoma Version 2. 2023 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf"},{"issue":"12","key":"10.1002\/14651858.CD015169-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015169-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015169-BIB0051|cit51","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015169-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015169-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD015169-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD015169-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","article-title":"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia","volume":"112","author":"Rassenti","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD015169-BIB0056|cit56","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"12","key":"10.1002\/14651858.CD015169-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.3390\/ijms24129930","article-title":"Molecular-biology-driven frontline treatment for chronic lymphocytic leukemia: a network meta-analysis of randomized clinical trials","volume":"24","author":"Rizzuto","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1002\/14651858.CD015169-BIB0058|cit58","first-page":"321","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"Rucker","year":"2021","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015169-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-armed studies in network meta-analysis","volume":"33","author":"Rucker","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015169-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015169-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD015169-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-21416-0_8","volume-title":"Meta-Analysis with R. Use R!","author":"Schwarzer","year":"2015"},{"key":"10.1002\/14651858.CD015169-BIB0063|cit63","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD015169-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"10232","key":"10.1002\/14651858.CD015169-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015169-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jrsm.44","article-title":"Meta-analysis of time-to-event data: a comparison of two-stage methods","volume":"2","author":"Simmonds","year":"2011","journal-title":"Research Synthesis Methods"},{"issue":"47","key":"10.1002\/14651858.CD015169-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"issue":"2","key":"10.1002\/14651858.CD015169-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"202\u20138","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD015169-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"21","key":"10.1002\/14651858.CD015169-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD015169-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA)","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015169-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD015169-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD015169-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1467-985X.00207","article-title":"The value of the aggregate data approach in meta-analysis with time-to-event outcomes","volume":"164","author":"Tudur","year":"2001","journal-title":"Journal of the Royal Statistical Society: Series A. Statistics in Society"},{"key":"10.1002\/14651858.CD015169-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015169-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata Journal: Promoting Communications on Statistics and Stata"},{"issue":"10","key":"10.1002\/14651858.CD015169-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2008.18.1701","article-title":"Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment","volume":"27","author":"Wierda","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015169-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"26","key":"10.1002\/14651858.CD015169-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015169-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.04.018","article-title":"Development of the summary of findings table for network meta-analysis","volume":"115","author":"Yepes-Nu\u00f1ez","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"issue":"29","key":"10.1002\/14651858.CD015169-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T15:57:47Z","timestamp":1730303867000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015169"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":81,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015169","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}